Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal doxorubicin + apatinib + camrelizumab
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
The combination of liposomal doxorubicin, apatinib, and camrelizumab is an investigational chemo-immunotherapy regimen being evaluated for the treatment of advanced or unresectable dedifferentiated liposarcoma (DDLPS). Liposomal doxorubicin is a nanoparticle-encapsulated anthracycline that inhibits DNA synthesis and topoisomerase II. Apatinib is a small-molecule tyrosine kinase inhibitor that selectively targets VEGFR-2 to inhibit tumor angiogenesis. Camrelizumab is a humanized monoclonal antibody that blocks the PD-1 receptor, enhancing the immune system's ability to detect and destroy tumor cells. This triplet therapy, sponsored by Fudan University in clinical trials, aims to overcome the limited efficacy of standard monotherapies in DDLPS by combining cytotoxic, anti-angiogenic, and immunomodulatory mechanisms.
- Other names
- liposomal doxorubicin hydrochloride + apatinib + camrelizumabliposomal doxorubicin + apatinib + SHR-1210
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)TOP2A (DNA topoisomerase II)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on liposomal doxorubicin + apatinib + camrelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal doxorubicin + apatinib + camrelizumab.